Laura Vásquez1, José V Scorza Dagert2, José V Scorza2, Nelson Vicuña-Fernández3, Yaneira Petit de Peña4, Sabrina López4, Herminia Bendezú2, Elina Rojas2, Libia Vásquez3, Belén Pérez2. 1. University of The Andes, Faculty of Medicine, Valera School of Medicine, Laboratory of Pharmacology, Valera, Venezuela ; University of The Andes, Center of Parasitological Investigations, José Witremundo Torrealba, NURR, Trujillo, Venezuela. 2. University of The Andes, Center of Parasitological Investigations, José Witremundo Torrealba, NURR, Trujillo, Venezuela. 3. University of The Andes, Faculty of Medicine, Valera School of Medicine, Laboratory of Pharmacology, Valera, Venezuela. 4. University of The Andes, Faculty of Sciences, Laboratory of MolecularSpectroscopy, La Hechicera, Venezuela.
Abstract
BACKGROUND: Pentavalent antimony (SbV) has demonstrated therapeuticeffectiveness against clinical manifestations of leishmaniasis, an infection caused by Leishmania, a genus of flagellate protozoa comprising parasites of worldwide distribution. Approximately 1.8 million new cases are reported annually. OBJECTIVE: The aim of this study was to assess the pharmacokinetics of the investigational generic SbV, Ulamina (pentachloride of antimony + N-methylglucamine), in healthy adult volunteers. METHODS: In this study, SbV was administered IM as a single 5-mg/kg dose.Blood samples were collected at 0.25, 0.75, 1, 2, 4, 8, 12, and 24 hours after administration; urine samples were collected at 6-hour intervals during the 24-hour postadministration period. Determination of trivalent antimony, SbV, and total antimony concentrations in blood and urine samples was carried out using atomic absorption spectrometry. Clinical history was reviewed and the subjects were monitored before and after administration of SbV using physical examination, weight, and hepatic- and renal-function studies. The pharmacokinetic parameters calculated were Cmax, Tmax, absorption constant (Ka), elimination constant (Kel), AUC2-24h, AUC0-∞, elimination phase (t½β), volume of distribution (Vd), and urinary excretion rate. RESULTS: Five subjects (3 men, 2 women; mean age, 28 years [range, 18-34 years]) were included in the study. One hour after drug administration the following values were obtained: Cmax, 1.1 μg/mL; Tmax, 1.3 hours; Ka, 1.87 hours; Kel, 0.043 hours; AUC0-24h, 12.26 μg/mL · h; AUC0-∞, 19.84 μg/mL · h; t½β, 17.45 hours; Vd, 6.6 L/kg; and urinary excretion rate, 2.8 μg/h; these were mean values for the entire study group. The single dose was well tolerated by all subjects. CONCLUSIONS: The investigational generic SbV, Ulamina, was associated with linearelimination after IM administration of a single 5-mg/kg dose. A 2-compartment pharmacokinetic model was observed in these volunteers; the mean t½β, was 17.45 hours and the mean Vd was 6.6 L/kg.
BACKGROUND: Pentavalent antimony (SbV) has demonstrated therapeuticeffectiveness against clinical manifestations of leishmaniasis, an infection caused by Leishmania, a genus of flagellate protozoa comprising parasites of worldwide distribution. Approximately 1.8 million new cases are reported annually. OBJECTIVE: The aim of this study was to assess the pharmacokinetics of the investigational generic SbV, Ulamina (pentachloride of antimony + N-methylglucamine), in healthy adult volunteers. METHODS: In this study, SbV was administered IM as a single 5-mg/kg dose.Blood samples were collected at 0.25, 0.75, 1, 2, 4, 8, 12, and 24 hours after administration; urine samples were collected at 6-hour intervals during the 24-hour postadministration period. Determination of trivalent antimony, SbV, and total antimony concentrations in blood and urine samples was carried out using atomic absorption spectrometry. Clinical history was reviewed and the subjects were monitored before and after administration of SbV using physical examination, weight, and hepatic- and renal-function studies. The pharmacokinetic parameters calculated were Cmax, Tmax, absorption constant (Ka), elimination constant (Kel), AUC2-24h, AUC0-∞, elimination phase (t½β), volume of distribution (Vd), and urinary excretion rate. RESULTS: Five subjects (3 men, 2 women; mean age, 28 years [range, 18-34 years]) were included in the study. One hour after drug administration the following values were obtained: Cmax, 1.1 μg/mL; Tmax, 1.3 hours; Ka, 1.87 hours; Kel, 0.043 hours; AUC0-24h, 12.26 μg/mL · h; AUC0-∞, 19.84 μg/mL · h; t½β, 17.45 hours; Vd, 6.6 L/kg; and urinary excretion rate, 2.8 μg/h; these were mean values for the entire study group. The single dose was well tolerated by all subjects. CONCLUSIONS: The investigational generic SbV, Ulamina, was associated with linearelimination after IM administration of a single 5-mg/kg dose. A 2-compartment pharmacokinetic model was observed in these volunteers; the mean t½β, was 17.45 hours and the mean Vd was 6.6 L/kg.
Authors: C Belloli; L Ceci; S Carli; P Tassi; C Montesissa; G De Natale; G Marcotrigiano; P Ormas Journal: Res Vet Sci Date: 1995-03 Impact factor: 2.534
Authors: Abdulrahman A Alrajhi; Elfaki A Ibrahim; Edward B De Vol; Mohammad Khairat; Rajab M Faris; James H Maguire Journal: N Engl J Med Date: 2002-03-21 Impact factor: 91.245
Authors: S Sundar; P R Sinha; N K Agrawal; R Srivastava; P M Rainey; J D Berman; H W Murray; V P Singh Journal: Am J Trop Med Hyg Date: 1998-07 Impact factor: 2.345
Authors: Débora Cristina de Oliveira Bezerra; Renata Oliveira de Barcelos; Ellen Carvalho de Castro; Claudia Cristina Jardim Duarte; Raquel de Vasconcellos Carvalhaes Oliveira; Tania Salgado de Sousa Torraca; Maria Helena de Araújo-Melo; Frederico Pereira Bom Braga; Benivaldo Ramos Ferreira Terceiro; Lúcia Regina do Nascimento Brahim Paes; Armando de Oliveira Schubach; Cláudia Maria Valete-Rosalino Journal: PLoS One Date: 2017-01-03 Impact factor: 3.240
Authors: Jingxin Li; Qian Wang; Ronald S Oremland; Thomas R Kulp; Christopher Rensing; Gejiao Wang Journal: Appl Environ Microbiol Date: 2016-08-30 Impact factor: 4.792
Authors: Jairo E Perez-Franco; Mónica L Cruz-Barrera; Marta L Robayo; Myriam C Lopez; Carlos D Daza; Angela Bedoya; Maria L Mariño; Carlos H Saavedra; Maria C Echeverry Journal: PLoS Negl Trop Dis Date: 2016-05-31
Authors: Madelon Novato Ribeiro; Maria Inês Fernandes Pimentel; Armando de Oliveira Schubach; Raquel de Vasconcellos Carvalhães de Oliveira; José Liporage Teixeira; Madson Pedro da Silva Leite; Monique Fonseca; Ginelza Peres Lima dos Santos; Mariza Matos Salgueiro; Erica de Camargo Ferreira e Vasconcellos; Marcelo Rosandiski Lyra; Mauricio Naoto Saheki; Claudia Maria Valete-Rosalino Journal: Rev Inst Med Trop Sao Paulo Date: 2014 Jul-Aug Impact factor: 1.846